Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

/p>

DIO-902 is an oral, once-daily drug being developed for the treatment of type 2 diabetes. It is a single enantiomer of racemic ketoconazole which suppresses cortisol production by inhibiting the 11 beta hydroxylase enzyme, the terminal step in the adrenal synthesis of cortisol. This novel mechanism of action makes DIO-902 a first-in-category cortisol inhibitor.

"Our unique approach to inhibition of cortisol synthesis offers the potential to address one of the underlying causes of type 2 diabetes, as well as multiple co-morbidities associated with both the disease, and its precursor, metabolic syndrome," said David A. Cory, Chief Executive Officer of DiObex, Inc. "DIO-902 offers patients the promise of effectively managing glycemia and lipids with a single medication. We are excited about the preliminary data generated to date and are rapidly progressing DIO-902 to the next stage of clinical development."

Data from various preclinical, epidemiological and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of the metabolic syndrome and type 2 diabetes.

The two-week trial with DIO-902 enrolled 37 patients with type 2 diabetes who were randomized to placebo, three different doses of DIO-902 ( 200 mg, 400 mg and 600 mg) or ketoconazole. Patients were either drug naove or on metformin, and had lipid-lowering agents washed out for at least 21 days prior to the first dose of the study drug. No serious adverse effects related to the study drug were reported. Liver function tests were carefully monitored, and no clinically meaningful changes were observed in any of the treated subjects. In fact, a number of subjects enrolled with mild transaminase elevations normalized during the two week treatment.

DiObex will conduct a multi-center, 16-week, phase 2b dose-ranging study with DIO-902; this study is scheduled to start enrolling patien
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... addition of Kent Hance , the former chancellor of ... Hance retired as chancellor in July 2014, after raising $1.2 ... announce that Kent Hance , the most successful chancellor ... Kiromic team not only as an investor, but also as ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the Deutsche Bank 36th Annual ... presentation takes place on Wednesday, May 4, 2011 at 10:40 ... will be webcast and may be accessed on the Company,s ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 ... and chief financial officer at Amylin Pharmaceuticals, will provide a ... through the "Investors" section of Amylin,s corporate website at ...
Cached Medicine Technology:
(Date:9/19/2014)... (PRWEB) September 19, 2014 “Copay coupons,” ... sales of brand drugs among patients with prescription drug ... according to a new report from the Department ... General (OIG). Federal anti-kickback laws prohibit suppliers from offering ... by the federal government. , The report highlights that ...
(Date:9/19/2014)... 2014 BearCom, a nationwide provider ... the key role played by instant, one-to-one and ... healthcare industry. , “In healthcare, speed of ... and in emergency situations, can save precious seconds ... death,” said Hugh Johnston, Product & Purchasing Manager ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2
... endoscopy is a well accepted tool for evaluation of ... some limitations due to restricted recording time and reduced ... preparation (e.g., prokinetic drugs, laxatives and defoaming agents) have ... However, to date no standardized protocol has been recommended ...
... with pancreatico-biliary carcinoma has been reported as a definite ... This study, performed by a team led by Professor ... in a research article to be published on April ... , The study evaluated 31 patients who underwent paraaortic ...
... SAN ANTONIO, May 20 Medco Health Solutions,Inc. ... benefit manager, and,Healthways (Nasdaq: HWAY ), the ... announced the opening of an innovative new,center that ... managing health risks and chronic conditions. The Medco ...
... Recognized Nationally-, WASHINGTON, May 20 Michelle Mays, ... Advocate of the Year,by the Campaign for Tobacco-Free Kids ... being honored at a gala in the nation,s,capital on ... winner,three other regional winners and a group winner., ...
... in the Water Just Like ... BioLab ... marketing communications agency, Fletcher Martin (, http://www.fletchermartin.com ) launched an interactive ... http://www.biolabuv.com ). The,banner-ad game is designed to entice consumers to ...
... available in Spanish . , , A research team from ... on the psychological process that triggers the craving or intense desire ... the brain mechanisms that activate this state and how to control ... Department of Personality, Evaluation and Psychological Treatment of the ...
Cached Medicine News:Health News:How does sodium phosphate combined with bisacodyl affect small intestine? 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 3Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 4Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 5Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Fletcher Martin Creates Interactive Game-Ad for BioLab(R) UV for BioGuard(R) 2Health News:A research on 'craving' for tobacco establishes the bases for addiction control 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: